Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 (Everolimus) in Recurrent Glioblastoma Multiforme
NCT00515086Phase 2Terminated
- Sponsor
- Novartis
- Start
- Aug 2007
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of everolimus in glioblastoma multiforme (GBM) (4 arms), sponsored by Novartis. Primary endpoints: Percentage Change From the Baseline in S6 Kinase Levels and Best Overall Tumor Response up to 60 weeks. Started Aug 2007; status: terminated.
02
Drugs
everolimus
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00515086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00515086.